Abstract 917P
Background
Patients with oral cavity squamous cell carcinoma (OCSCC) are at high risk of death within 5 years of treatment. Previous works have demonstrated that spatial arrangement of tumor-infiltrating lymphocytes (TILs) and surrounding nuclei (e.g, cancer nuclei, macrophages, fibroblasts) is prognostic of overall survival (OS) in different types of cancer, including oropharyngeal and laryngeal. In this work, we evaluated the prognostic ability of a computerized strategy that characterizes the spatial arrangement of TILs & non-TILs on digitized H&E-stained slides of patients with OCSCC.
Methods
Whole slide images (WSIs) from a cohort of 283 patients with OCSCC were retrospectively collected from the Cancer Genome Atlas (TCGA, D1). Additionally, WSIs from 136 patients with OCSCC were obtained from Vanderbilt University Medical Center (VUMC, D2). D1 was used to train a prognostic model while D2 was used for independent validation. Computer algorithms automatically identified 2 types of nuclei (TILs & non-TILs) and built clusters for each nucleus type based on proximity. Metrics related to density, intersection, and neighborhood were computed from these clusters. A proportional hazard Cox regression model, regularized via the least absolute shrinkage and selection operator, was trained to predict risk of death. The percentile 66 risk score on D1 was used as a threshold for stratifying patients on D2 as either low or high risk. Survival analysis was then used to evaluate the association with OS.
Results
Patients in D2 defined as “low risk” (57%) based on spatial arrangement of TILs has significantly better OS than those identified as “high risk” (43%) with hazard ratio=3.84 (95% confidence interval: 1.39-10.6, p<0.01). Multivariable survival analysis showed that this model was prognostic independent of age and overall, T, and N stages with HR=2.88 (95% CI: 1.10-7.56, p=0.03).
Conclusions
A computerized image analysis model based on measurements of spatial arrangement of TILs & non-TILs was found to be prognostic in patients with OCSCC. With more modeling and development, this model may provide a risk classifier for use in routine clinical practice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
A. Madabhushi.
Funding
US National Institutes of Health, US Department of Defense.
Disclosure
A. Madabhushi: Financial Interests, Personal, Advisory Board, Serve on SAB and consult: SimbioSys; Financial Interests, Personal, Advisory Board: Aiforia, Picture Health; Financial Interests, Personal, Full or part-time Employment: Picture Health; Financial Interests, Personal, Ownership Interest: Picture Health, Elucid Bioimaging, Inspirata Inc; Financial Interests, Personal, Royalties: Picture Health, Elucid Bioimaging; Financial Interests, Institutional, Funding: AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly. All other authors have declared no conflicts of interest.
Resources from the same session
1056P - Real-world usage and adverse events (AE) of immune checkpoint inhibitors (ICI): A large-scale, automated, GDPR-compliant analysis of hospital records
Presenter: Annelies Verbiest
Session: Poster session 03
1057P - Blinded independent central review versus local investigator assessment of progression-free survival in randomized controlled trials of immunotherapy in advanced cancers: A systematic review and meta-analysis
Presenter: Simeone D'Ambrosio
Session: Poster session 03
1058P - Hyperprogressive disease during immune checkpoint inhibitor: A cloudy phenomenon with real consequences
Presenter: Damien Bruyat
Session: Poster session 03
1059P - Association between tumor longevity and immune-checkpoint inhibitor outcomes: A retrospective study in head and neck, lung, renal/urothelial cancers
Presenter: Rebecca Romanò
Session: Poster session 03
1060P - Comparative investigation of neoadjuvant immunotherapy versus adjuvant immunotherapy in perioperative patients with cancer: A metrology informatics analysis based on machine learning
Presenter: Song-Bin Guo
Session: Poster session 03
1061P - Assessing differential informative censoring in control and experimental arm in trials testing immunotherapy in metastatic cancers: A systematic review
Presenter: Filippo Vitale
Session: Poster session 03
1062P - Effect of the immunological circadian rhythm on the treatment of locally advanced non-small cell lung cancer treated with consolidation immunotherapy
Presenter: Èlia Sais
Session: Poster session 03
1063P - Influence of infusion timing on the outcomes of immunotherapy in a multi-tumor cohort
Presenter: Víctor Albarrán Fernández
Session: Poster session 03